TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31395900
Drug: FOLFOX-4 or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-4 or XELOX adjuvant chemotherapy for 6 months
Study: 26239323
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion vancomycin (target random levels, 20‐30 mg/L)
Study: 24077095
Drug: Mometasone furoate/formoterol
Normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate/formoterol (MF/F) 400 μg/10 μg
Study: 24077095
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol (FP/S) 460 μg/42 μg
Study: 24077095
Drug: Mometasone furoate/formoterol
Normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate/formoterol (MF/F) 200 μg/10 μg
Study: 7998413
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml HBIg at birth followed by hepatitis B immunization (20 micrograms) at 3, 4, 5 and 11 months (schedule E)
Study: 7998413
Drug: Plasma vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma vaccine (10 micrograms) according to schedule F (historic controls)
Study: 30188231
Drug: Pembrolizumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab + chemotherapy (carboplatin/cisplatin + pemetrexed)
Study: 23712757
Drug: Danoprevir 100
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir 100 mg and Ritonavir 100 mg co-administered with Ciclosporin 100 mg
Study: 23712757
Drug: Danoprevir 100
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir 100 mg and Ritonavir 100 mg
Study: 23712757
Drug: Ciclosporin 100
Normalized name: Ciclosporin 100 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin 100 mg
Study: 16820345
Drug: Magnesium potassium
Normalized name: MAGNESIUM POTASSIUM ALUMINOSILICATE FLUORIDE
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium potassium supplementation (magnesium, 70.8 mg/d; potassium, 217.2 mg/d) for four weeks
Study: 16820345
Drug: Lacidipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (4 mg/d) as control
Study: 11119328
Drug: Focal spraying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal spraying with deltamethrin 5% SC at 25 mg a. i./m2 (PT group)
Study: 8763182
Drug: Cefuroxime (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (30 mg/kg) at induction of anaesthesia
Study: 1707255
Drug: Esophageal intubation
Normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esophageal intubation followed by radiation therapy (AT/RT)
Study: 1707255
Drug: Endoscopic laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic laser therapy followed by irradiation (L/RT)
Study: 1707255
Drug: L/RT group
Approvals — FDA: no, EMA: no, PMDA: no
Description: L/RT group
Study: 6177981
Drug: Oral human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral human gammaglobulin
Study: 31959601
Drug: 3D intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D intervention (comprehensive 6‐monthly general practitioner consultations, supported by medication reviews and nurse appointments)
Study: 26031828
Drug: Arg infusion
Normalized name: Arg
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arg infusion (0.5 g/kg, 30 min)
Study: 26031828
Drug: Daily Arg
Normalized name: Arg
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily Arg ingestion (10 g)
Study: 23906999
Drug: Topiramate (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100-300 mg/day)
Study: 19555253
Drug: Fenofibrate 145
Normalized name: fenofibrate 145 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 145 mg/day + Simvastatin 40 mg/day
Study: 15390343
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose alcohol (1.6 +/- 0.4 ml)
Study: 15390343
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose alcohol (3.4 +/- 0.9 ml)
Study: 10197074
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 6 i.u. s.c. twice daily from 2 days before until 7 days after surgery
Study: 10197074
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) and Placebo
Study: 7815310
Drug: rec-hirudin, 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rec-hirudin, 0.1 mg/kg
Study: 7815310
Drug: rec-hirudin, 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: rec-hirudin, 0.3 mg/kg
Study: 7815310
Drug: rec-hirudin, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rec-hirudin, 0.5 mg/kg
Study: 7815310
Drug: rec-hirudin, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rec-hirudin, 1 mg/kg
Study: 7815310
Drug: rec-hirudin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: rec-hirudin (all doses)
Study: 25342652
Drug: Endovascular therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapies (EVTs)
Study: 18687539
Drug: Tibolone (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (1.25 mg/day women's equivalent)
Study: 18687539
Drug: Soy +
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy + Tibolone (138 mg isoflavones/day women's equivalent)
Study: 18687539
Drug: Soy (52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy (52 g of soy protein containing 112 mg isoflavones)
Study: 18687539
Drug: Placebo (52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (52 g of milk protein)
Study: 16822116
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) plus fluoxetine
Study: 12566778
Drug: PGE(1) gel
Normalized name: PGE-1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE(1) gel administered in the ambulatory form (group 1)
Study: 12566778
Drug: PGE(1) gel
Normalized name: PGE-1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE(1) gel administered in the labor room (group 2)
Study: 12566778
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered oxytocin (group 3)
Study: 9198048
Drug: High-efficiency haemodialysis
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-efficiency haemodialysis (dialyser blood flow rate = 400 ml/min; dialysis time = 170.67 min)
Study: 9198048
Drug: Standard haemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard haemodialysis (dialyser blood flow rate = 200 ml/min; dialysis time = 240 min)
Study: 2580678
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of amino acids (100 ml/hr 10%)
Study: 2580678
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of fat (100 ml/hr 10%)
Study: 2580678
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of glucose (150 ml/hr 10%)
Study: 2580678
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of higher glucose dose (100 ml 20% glucose as a bolus followed by 300 ml/hr 10%)
Study: 19422632
Drug: Conventional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional care and treatment (Control)
Study: 10441861
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of trometamol salt of thioctic (alpha-lipoic) acid (Thioctacid 600) in 200 ml of physiological solution
Study: 10441861
Drug: Placebo (physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (physiological solution stained with 1% solution of riboflavin mononucleate)
Study: 2217893
Drug: Intramuscular P
Normalized name: BayRHo-D, intramuscular powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular P (group B)
Study: 2217893
Drug: Intramuscular P
Normalized name: BayRHo-D, intramuscular powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular P and hCG (group C)
Study: 2217893
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (intramuscular P and hCG)
Study: 29296811
Drug: Regadenoson (1.44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadenoson (1.44 μg/kg per hour)
Study: 25574111
Drug: Clarithromycin-based triple
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin-based triple therapy (PAC group: rabeprazole, amoxicillin, clarithromycin)
Study: 25574111
Drug: Metronidazole-based triple
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole-based triple therapy (PAM group: rabeprazole, amoxicillin, metronidazole)
Study: 25574111
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (rabeprazole and amoxicillin followed by rabeprazole, clarithromycin and metronidazole)
Study: 25574111
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (rabeprazole, amoxicillin, clarithromycin and metronidazole)
Study: 23548622
Drug: Subconjunctival sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival sirolimus (440 μg) administered every 3 months for 24 months
Study: 19834019
Drug: Microplasmin 3
Normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Microplasmin 3 mg/kg
Study: 19834019
Drug: Microplasmin 4
Normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Microplasmin 4 mg/kg
Study: 24929548
Drug: Video-assisted oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-assisted oral debriefing (VAOD)
Study: 24929548
Drug: Oral debriefing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral debriefing alone (ODA)
Study: 20338560
Drug: Endometrial biopsy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial biopsy treatment on days 8 or/and 11 to 13 of the menstrual cycle
Study: 20338560
Drug: Endometrial biopsy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial biopsy treatment
Study: 20338560
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no biopsy treatment)
Study: 18669897
Drug: Ordinal statistical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinal statistical tests (e.g., bootstrapping the difference in mean rank, Mann‐Whitney U test, ordinal logistic regression)
Study: 15866563
Drug: Yohimbine (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (higher dose)
Study: 1781563
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.4 mg/kg)
Study: 1781563
Drug: Rectal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal midazolam (0.5 mg/kg)
Study: 1781563
Drug: Nasal midazolam
Normalized name: midazolam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal midazolam (0.2 mg/kg)
Study: 30727929
Drug: Herbal compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal compound (one sachet twice daily for 12 weeks) containing 300 mg Aloe vera, 1.8 g black seed, 300 mg garlic, 2.5 g fenugreek seed, 1 g psyllium seed, 500 mg milk thistle seed
Study: 30727929
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with hypolipidemic and hypoglycemic drugs
Study: 27908974
Drug: Humor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humor therapy program
Study: 25295681
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (CT) with selected nutraceuticals
Study: 9002118
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin 10 mg/kg every 8 h for 7 days followed by oral ciprofloxacin 20 mg/kg every 12 h for a minimum of 3 days
Study: 9002118
Drug: Ceftazidime 50
Normalized name: ceftazidime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 50 mg/kg every 8 h plus tobramycin 3 mg/kg every 8 h for a minimum of 10 days
Study: 9002118
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (ciprofloxacin and ceftazidime/tobramycin)
Study: 23580011
Drug: Long-term oral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oral contraceptives (OCs) therapy with different progestins (desogestrel, gestodene, dienogest)
Study: 23580011
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients who refused postoperative hormonal therapy)
Study: 20307355
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g alpha-lactalbumin (LAC; l-tryptophan (Trp):large neutral amino acids (LNAA) ratio of 7.6)
Study: 20307355
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g casein (placebo; Trp:LNAA ratio of 4.0)
Study: 18262575
Drug: 0.3 M
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 M sucrose solution
Study: 18262575
Drug: 0.15 M
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 M NaCl solution (unpleasant stimulus)
Study: 8639883
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human erythropoietin (rhEPO) 10,000 U/d subcutaneously 7 days a week (fixed dose group)
Study: 8639883
Drug: rhEPO 2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO 2,000 U/d subcutaneously for 8 weeks followed by step‐wise escalation of the rhEPO dose (titration group)
Study: 8639883
Drug: no rhEPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: no rhEPO therapy (control group)
Study: 1598788
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of 2 x 10(9) bacteria
Study: 1598788
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of the vaccine
Study: 6529523
Drug: Tiapamil (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil (450 mg single oral dose)
Study: 6529523
Drug: Tiapamil (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil (450 mg twice daily)
Study: 26993628
Drug: Quilizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quilizumab (300 mg monthly)
Study: 26993628
Drug: Quilizumab (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quilizumab (monthly or quarterly dosing)
Study: 25276983
Drug: Xingnaojing Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingnaojing Injection combined with minimally invasive percutaneous drainage
Study: 22742438
Drug: Bright white
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white light (BWL) therapy for 30 min every morning during chemotherapy
Study: 22742438
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light (DRL) therapy for 30 min every morning during chemotherapy
Study: 22742438
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light (DRL) therapy
Study: 22742438
Drug: Bright white
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white light (BWL) therapy
Study: 19656432
Drug: Open continued
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open continued treatment phase
Study: 17509068
Drug: Structured care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured care (hospital outpatient clinic with initial 6 months' lifestyle programme followed by intensified pharmacological treatment)
Study: 17509068
Drug: Intensified pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified pharmacological treatment (6-24 months)
Study: 15843080
Drug: Rifaximin 800
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 800 mg/day for 10 days
Study: 11860405
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg b.d. alosetron
Study: 11860405
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg b.d. alosetron
Study: 27267614
Drug: Interleukin 2
Normalized name: Recombinant interleukin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin 2 receptor antagonist
Study: 27267614
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (low and high panel reactive antibody)
Study: 25686324
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (SRP + antibiotics: metronidazole 0.2 g tid for 7 days, amoxicillin 0.5 g tid for 7 days)
Study: 25686324
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (SRP followed by antibiotics: metronidazole 0.2 g tid for 7 days, amoxicillin 0.5 g tid for 7 days starting 1 day after SRP)
Study: 21803755
Drug: Respiratory modulation
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory modulation (RM) device, 20 min sessions twice daily for 4 weeks
Study: 21803755
Drug: Music listening
Normalized name: Listerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music listening (ML) using a CD player, control group
Study: 15589864
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg anastrozole
Study: 15589864
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg anastrozole
Study: 15589864
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg anastrozole
Study: 15589864
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg anastrozole
Study: 15589864
Drug: five daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: five daily doses of 10 mg or 15 mg anastrozole
Study: 12359281
Drug: IV 0.1
Normalized name: Immphentiv 0.1 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV 0.1 mg/Kg chlorpromazine (CPZ)
Study: 22379743
Drug: Dexpanthenol nasal
Normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexpanthenol nasal spray
Study: 335490
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g daily for four weeks
Study: 335490
Drug: Inactive tablets
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive tablets (control)
Study: 31278094
Drug: 1000 mg/day
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day trans-resveratrol for 8 weeks
Study: 28638702
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day Rosuvastatin
Study: 28638702
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day Rosuvastatin
Study: 11491417
Drug: Zidovudine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (300 mg twice per day) plus Lamivudine (150 mg twice per day) plus Nelfinavir placebo (three times per day)
Study: 11491417
Drug: Zidovudine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (300 mg twice per day) plus Lamivudine (150 mg twice per day) plus Nelfinavir (750 mg three times per day)
Study: 11491417
Drug: Zidovudine/lamivudine/nelfinavir (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine/lamivudine/nelfinavir (after switching from double nucleoside therapy)
Study: 11491417
Drug: Zidovudine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (300 mg twice per day) plus Lamivudine (150 mg twice per day)
Study: 29987421
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) after adjustment for FIV
Study: 23664040
Drug: Light emitting
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light emitting diode therapy (LEDT)
Study: 21859685
Drug: Ofatumumab 700
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 700 mg (two infusions, 2 weeks apart)
Study: 17610057
Drug: Tomatis Method
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomatis Method (Treatment)
Study: 16859505
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) at an initial dose of 200 microg x kg‐1 after transfusion of eight red blood cell units, followed by additional doses of 100 microg x kg‐1, one and three hours later